Evidence map›Paper›PMID 21674360›Full record

ArticleInternational journal of hematology2011

Expression of myeloperoxidase and gene mutations in AML patients with normal karyotype: double CEBPA mutations are associated with high percentage of MPO positivity in leukemic blasts.

Shinya Tominaga-Sato, Hideki Tsushima, Koji Ando, Hidehiro Itonaga, Yoshitaka Imaizumi, Daisuke Imanishi, Masako Iwanaga, Jun Taguchi, Takuya Fukushima, Shinichiro Yoshida and 6 more

Erratum issuedOpen access · greenAbstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

16 authors at 7 institutions in 1 country.

Shinya Tominaga-SatoDepartment of Hematology and Molecular Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan.
Hideki TsushimaDepartment of Hematology, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan. tsushima@nagasaki-u.ac.jp.
Koji AndoDepartment of Internal Medicine, Nagasaki National Medical Center, Ohmura, Nagasaki, Japan.
Hidehiro ItonagaDepartment of Hematology and Molecular Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan.
Yoshitaka ImaizumiDepartment of Hematology, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Daisuke ImanishiDepartment of Hematology, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Masako IwanagaDepartment of Hematology and Molecular Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan.
Jun TaguchiDepartment of Hematology and Molecular Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan.
Takuya FukushimaDepartment of Hematology, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Shinichiro YoshidaDepartment of Internal Medicine, Nagasaki National Medical Center, Ohmura, Nagasaki, Japan.
Tomoko HataDepartment of Hematology, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Yukiyoshi MoriuchiDivision of Hematology, Sasebo City General Hospital, Sasebo, Nagasaki, Japan.
Kazutaka KuriyamaSchool of Health Sciences, University of the Ryukyus, Okinawa, Nishihara, Japan.
Hiroyuki ManoDivision of Functional Genomics, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Masao TomonagaDepartment of Hematology, Japanese Red-Cross Nagasaki Atomic Bomb Hospital, Nagasaki, Nagasaki, Japan.
Yasushi MiyazakiDepartment of Hematology and Molecular Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan.
Nagasaki University · JPNagasaki University Hospital · JPNagasaki Medical Center · JPHiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital · JPJichi Medical University · JPSasebo City General Hospital · JPUniversity of the Ryukyus · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The percentage of myeloperoxidase (MPO)-positive blast cells is a simple and highly significant prognostic factor in AML patients. It has been reported that the high MPO group (MPO-H), in which >50% of blasts are MPO activity positive, is associated with favorable karyotypes, while the low MPO group (≤50% of blasts are MPO activity positive, MPO-L) is associated with adverse karyotypes. The MPO-H group shows better survival even when restricted to patients belonging to the intermediate chromosomal risk group or those with a normal karyotype. It has recently been shown that genotypes defined by the mutational status of NPM1, FLT3, and CEBPA are associated with treatment outcome in patients with cytogenetically normal AML. In this study, we aimed to evaluate the relationship between MPO positivity and gene mutations found in normal karyotypes. Sixty AML patients with normal karyotypes were included in this study. Blast cell MPO positivity was assessed in bone marrow smears stained for MPO. Associated genetic lesions (the NPM1, FLT3-ITD, and CEBPA mutations) were studied using nucleotide sequencing. Thirty-two patients were in the MPO-L group, and 28 patients in the MPO-H group. FLT3-ITD was found in 11 patients (18.3%), NPM1 mutations were found in 19 patients (31.7%), and CEBPA mutations were found in 11 patients (18.3%). In patients with CEBPA mutations, the carrying two simultaneous mutations (CEBPA (double-mut)) was associated with high MPO expression, while the mutant NPM1 without FLT3-ITD genotype was not associated with MPO activity. Both higher MPO expression and the CEBPA (double-mut) genotype appeared to be associated with improved overall survival after intensive chemotherapy. Further studies are required to determine the importance of blast MPO activity as a prognostic factor, especially in CEBPA wild-type patients with a normal karyotype.

Indexed as

MutationBlast CrisisCCAAT-Enhancer-Binding Proteinsfms-Like Tyrosine Kinase 3Gene Expression Regulation, LeukemicGenes, NeoplasmHumansKaryotypeLeukemia, Myeloid, AcuteNuclear ProteinsNucleophosminPeroxidaseSurvival RateCCAAT-Enhancer-Binding ProteinsCEBPA protein, humanFLT3 protein, humanfms-Like Tyrosine Kinase 3NPM1 protein, humanNuclear ProteinsNucleophosminPeroxidase

Identifiers

PMID21674360
OpenAlexW2046353917

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.